Why Did United Therapeutics Plunge 12.89%?

Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 10, 2025 7:32 am ET1min read

On June 10, 2025,

experienced a significant drop of 12.89% in pre-market trading, sparking concerns among investors about the company's future prospects.

JPMorgan Chase & Co. recently adjusted their outlook on

lowering their price target from $355.00 to $350.00 while maintaining an "overweight" rating. This revision reflects the bank's updated analysis of the company's financial performance and market position.

Two Sigma Investments LP has also made notable moves, acquiring 52 shares of United Therapeutics. This investment signals confidence in the company's long-term growth potential, despite recent market volatility.

Comments



Add a public comment...
No comments

No comments yet